Pharmacological Treatments and Natural Biocompounds in Weight Management

The obesity pandemic is one of society’s most urgent public health concerns. One-third of the global adult population may fall under obese or overweight by 2025, suggesting a rising demand for medical care and an exorbitant cost of healthcare expenditure in the coming years. Generally, the treatment strategy for obese patients is largely patient-centric and needs dietary, behavioral, pharmacological, and sometimes even surgical interventions. Given that obesity cases are rising in adults and children and lifestyle modifications have failed to produce the desired results, the need for medical therapy adjunct to lifestyle modifications is vital for better managing obesity. Most existing or past drugs for obesity treatment target satiety or monoamine pathways and induce a feeling of fullness in patients, while drugs such as orlistat are targeted against intestinal lipases. However, many medications targeted against neurotransmitters showed adverse events in patients, thus being withdrawn from the market. Alternatively, the combination of some drugs has been successfully tested in obesity management. However, the demand for novel, safer, and more efficacious pharmaceutical medicines for weight management does exist. The present review elucidates the current understanding of the available anti-obesity medicines of synthetic and natural origin, their main mechanisms of action, and the shortcomings associated with current weight management drugs.

[1]  M. Peana,et al.  The Role of Astaxanthin as a Nutraceutical in Health and Age-Related Conditions , 2022, Molecules.

[2]  Monica Butnariu,et al.  Natural Compounds and Products from an Anti-Aging Perspective , 2022, Molecules.

[3]  L. Oyama,et al.  Ginkgo biloba Extract Stimulates Adipogenesis in 3T3-L1 Preadipocytes , 2022, Pharmaceuticals.

[4]  Jingxin Zhang,et al.  Multidisciplinary Progress in Obesity Research , 2022, Genes.

[5]  M. Peana,et al.  Polyphenols in Metabolic Diseases , 2022, Molecules.

[6]  Xi-Ding Yang,et al.  Potential lipolytic regulators derived from natural products as effective approaches to treat obesity , 2022, Frontiers in Endocrinology.

[7]  Sohita Dhillon Phentermine/Topiramate: Pediatric First Approval , 2022, Pediatric Drugs.

[8]  Meihong Xu,et al.  Adipose Tissue Aging and Metabolic Disorder, and the Impact of Nutritional Interventions , 2022, Nutrients.

[9]  Jailane de Souza Aquino,et al.  Effects of the Treatment with Flavonoids on Metabolic Syndrome Components in Humans: A Systematic Review Focusing on Mechanisms of Action , 2022, International journal of molecular sciences.

[10]  S. Bielinski,et al.  Association between CYP metabolizer phenotypes and selective serotonin reuptake inhibitors induced weight gain: a retrospective cohort study , 2022, BMC Medicine.

[11]  M. Konwar,et al.  Efficacy and Safety of Liraglutide 3.0 mg in Patients with Overweight and Obese with or without Diabetes: A Systematic Review and Meta-Analysis , 2022, International journal of clinical practice.

[12]  Jun Yu Li,et al.  Biomaterial-Based Therapeutic Strategies for Obesity and Its Comorbidities , 2022, Pharmaceutics.

[13]  W. Shi,et al.  Hypothesis: Amelioration of obesity‐induced cognitive dysfunction via a lorcaserin–betahistine combination treatment , 2022, Pharmacology research & perspectives.

[14]  D. Goulis,et al.  Anti-obesity Medications for the Management of Nonalcoholic Fatty Liver Disease , 2022, Current Obesity Reports.

[15]  E. Helal,et al.  Effects of the Antiobesity Drugs Aplex and Venera on Certain Biochemical and Physiological Indices in Obese Adult Male Albino Rats , 2022, Advances in pharmacological and pharmaceutical sciences.

[16]  W. Chung,et al.  Effects of electroacupuncture for obesity , 2022, Medicine.

[17]  Jiankang Cao,et al.  Anti-diabetic and anti-obesity: Efficacy evaluation and exploitation of polyphenols in fruits and vegetables. , 2022, Food research international.

[18]  R. Matos,et al.  Naltrexone/bupropion modifies weight, food intake, and Drd2 gene expression in rats. , 2022, The Journal of endocrinology.

[19]  Md. Rezaul Islam,et al.  The Multifunctional Role of Herbal Products in the Management of Diabetes and Obesity: A Comprehensive Review , 2022, Molecules.

[20]  M. Farré,et al.  Abuse Potential of Cathinones in Humans: A Systematic Review , 2022, Journal of clinical medicine.

[21]  A. Nicolucci,et al.  The adolescent with obesity: what perspectives for treatment? , 2022, Italian Journal of Pediatrics.

[22]  M. Lam,et al.  Dosing Therapeutic Radiopharmaceuticals in Obese Patients , 2022, International journal of molecular sciences.

[23]  D. Pellegrino,et al.  Efficacy of liraglutide 3.0 mg treatment on weight loss in patients with weight regain after bariatric surgery , 2021, Eating and Weight Disorders - Studies on Anorexia, Bulimia and Obesity.

[24]  G. Guyatt,et al.  Pharmacotherapy for adults with overweight and obesity: a systematic review and network meta-analysis of randomised controlled trials , 2021, The Lancet.

[25]  M. Horowitz,et al.  Newer generation antidepressants and withdrawal effects: reconsidering the role of antidepressants and helping patients to stop , 2021, Drug and Therapeutics Bulletin.

[26]  Lu Zhang,et al.  Comparison of Beinaglutide Versus Metformin for Weight Loss in Overweight and Obese Non-diabetic Patients , 2021, Experimental and clinical endocrinology & diabetes : official journal, German Society of Endocrinology [and] German Diabetes Association.

[27]  Beverly G. Tchang,et al.  Obesity and Diabetes. , 2021, The Nursing clinics of North America.

[28]  O. Meijer,et al.  Variation in glucocorticoid sensitivity and the relation with obesity , 2021, Obesity reviews : an official journal of the International Association for the Study of Obesity.

[29]  M. Tschöp,et al.  Anti-obesity drug discovery: advances and challenges , 2021, Nature reviews. Drug discovery.

[30]  C. Matthys,et al.  Liraglutide for Weight Management in the Real World: Significant Weight Loss Even if the Maximal Daily Dose Is Not Achieved , 2021, Obesity Facts.

[31]  D. Ryan Drugs for Treating Obesity. , 2021, Handbook of experimental pharmacology.

[32]  Ding Li,et al.  Lorcaserin Inhibit Glucose-Stimulated Insulin Secretion and Calcium Influx in Murine Pancreatic Islets , 2021, Frontiers in Pharmacology.

[33]  A. D’Anneo,et al.  The Beneficial Effects of Essential Oils in Anti-Obesity Treatment , 2021, International journal of molecular sciences.

[34]  C. Mantzoros,et al.  Novel Non-invasive Approaches to the Treatment of Obesity: From Pharmacotherapy to Gene Therapy. , 2021, Endocrine reviews.

[35]  N. Salari,et al.  The best drug supplement for obesity treatment: a systematic review and network meta-analysis , 2021, Diabetology & Metabolic Syndrome.

[36]  Y. Jee,et al.  Anti-obesity effect of sulforaphane in broccoli leaf extract on 3T3-L1 adipocytes and ob/ob mice. , 2021, The Journal of nutritional biochemistry.

[37]  H. Hauner [Obesity treatment-legal and illegal drugs and the future]. , 2021, Der Internist.

[38]  H. Hauner Adipositastherapie – legale und illegale Arzneimittel und die Zukunft , 2021, Der Internist.

[39]  R. Bove,et al.  Glucocorticoids for therapeutic immunosuppression: Clinical pearls for the practicing neurologist , 2021, Journal of the Neurological Sciences.

[40]  M. Kumar,et al.  Nano-Derived Therapeutic Formulations with Curcumin in Inflammation-Related Diseases , 2021, Oxidative medicine and cellular longevity.

[41]  Hyo-Jin An,et al.  Papain Ameliorates Lipid Accumulation and Inflammation in High-Fat Diet-Induced Obesity Mice and 3T3-L1 Adipocytes via AMPK Activation , 2021, International journal of molecular sciences.

[42]  J. Roncalli,et al.  Metformin Attenuates Postinfarction Myocardial Fibrosis and Inflammation in Mice , 2021, International journal of molecular sciences.

[43]  S. Robinson,et al.  Clinical outcomes associated with anti‐obesity medications in real‐world practice: A systematic literature review , 2021, Obesity reviews : an official journal of the International Association for the Study of Obesity.

[44]  R. Molinari,et al.  Polyphenols as modulators of pre‐established gut microbiota dysbiosis: State‐of‐the‐art , 2021, BioFactors.

[45]  I. C. Tudor,et al.  Effect of Miricorilant, a Selective Glucocorticoid Receptor Modulator, on Olanzapine-Associated Weight Gain in Healthy Subjects , 2021, Journal of clinical psychopharmacology.

[46]  S. Granica,et al.  Highbush Blueberry (Vaccinium corymbosum L.) Leaves Extract and Its Modified Arginine Preparation for the Management of Metabolic Syndrome—Chemical Analysis and Bioactivity in Rat Model , 2021, Nutrients.

[47]  A. Mirzababaei,et al.  Effect of orlistat on serum uric acid level in adults: A systematic review and meta‐analysis of randomised controlled trials , 2021, International journal of clinical practice.

[48]  V. Petrikaitė,et al.  Bio-guided bioactive profiling and HPLC-DAD fingerprinting of Ukrainian saffron (Crocus sativus stigmas): moving from correlation toward causation , 2021, BMC Complementary Medicine and Therapies.

[49]  Dhiren Patel,et al.  Patient initiation and maintenance of GLP-1 RAs for treatment of obesity , 2021, Expert review of clinical pharmacology.

[50]  M. Banach,et al.  Quercetin and metabolic syndrome: A review , 2021, Phytotherapy research : PTR.

[51]  K. Sharma,et al.  A Review on Obesity Management through Natural Compounds and a Green Nanomedicine-Based Approach , 2021, Molecules.

[52]  T. Gojobori,et al.  Leptin and Obesity: Role and Clinical Implication , 2021, Frontiers in Endocrinology.

[53]  R. Radice,et al.  Effects of astaxanthin in animal models of obesity-associated diseases: a systematic review and meta-analysis. , 2021, Free radical biology & medicine.

[54]  Jia Li,et al.  Mechanism of Action of Acupuncture in Obesity: A Perspective From the Hypothalamus , 2021, Frontiers in Endocrinology.

[55]  Hongjun Yang,et al.  Celastrol in Metabolic Diseases: Progress and Application Prospects. , 2021, Pharmacological research.

[56]  T. Lyons,et al.  Dietary Blueberry and Soluble Fiber Supplementation Reduces Risk of Gestational Diabetes in Women with Obesity in a Randomized Controlled Trial. , 2021, The Journal of nutrition.

[57]  P. Hellström,et al.  Safety of a Novel Weight Loss Combination Product Containing Orlistat and Acarbose , 2021, Clinical pharmacology in drug development.

[58]  A. Hichami,et al.  Antioxidant and Anti-Inflammatory Potential of Polyphenols Contained in Mediterranean Diet in Obesity: Molecular Mechanisms , 2021, Molecules.

[59]  M. Soto,et al.  Oxidative Stress, Plant Natural Antioxidants, and Obesity , 2021, International journal of molecular sciences.

[60]  M. Moorthy,et al.  Polyphenols as Prebiotics in the Management of High-Fat Diet-Induced Obesity: A Systematic Review of Animal Studies , 2021, Foods.

[61]  P. Taub,et al.  Time-Restricted Eating and Metabolic Syndrome: Current Status and Future Perspectives , 2021, Nutrients.

[62]  P. Hale,et al.  A randomized, controlled trial of liraglutide for adolescents with obesity , 2020 .

[63]  Ming Lyu,et al.  The potential of artemisinins as anti-obesity agents via modulating the immune system. , 2020, Pharmacology & therapeutics.

[64]  J. Pérez-Correa,et al.  Phlorotannins: From isolation and structural characterization, to the evaluation of their antidiabetic and anticancer potential. , 2020, Food research international.

[65]  M. Arshad,et al.  Health benefits of xylitol , 2020, Applied Microbiology and Biotechnology.

[66]  Xiang‐Dong Wang,et al.  Lycopene in protection against obesity and diabetes: A mechanistic review. , 2020, Pharmacological research.

[67]  K. Gadde,et al.  The limits and challenges of antiobesity pharmacotherapy. , 2020, Expert opinion on pharmacotherapy.

[68]  P. Hale,et al.  A Randomized, Controlled Trial of Liraglutide for Adolescents with Obesity. , 2020, The New England journal of medicine.

[69]  E. Harasim-Symbor,et al.  Phytocannabinoids: Useful Drugs for the Treatment of Obesity? Special Focus on Cannabidiol , 2020, Frontiers in Endocrinology.

[70]  W. Garvey,et al.  Efficacy and Safety of Liraglutide 3.0 mg in Individuals With Overweight or Obesity and Type 2 Diabetes Treated With Basal Insulin: The SCALE Insulin Randomized Controlled Trial , 2020, Diabetes Care.

[71]  M. T. Islam,et al.  Anti‐obesity effect of plant diterpenes and their derivatives: A review , 2020, Phytotherapy research : PTR.

[72]  S. Engeli,et al.  Modern pharmacological treatment of obese patients , 2020, Therapeutic advances in endocrinology and metabolism.

[73]  T. Meng,et al.  The effect of beinaglutide on visceral fat and bodyweight in obese type 2 diabetic patients , 2020 .

[74]  S. Chirumbolo,et al.  Calanus oil in the treatment of obesity-related low-grade inflammation, insulin resistance, and atherosclerosis , 2019, Applied Microbiology and Biotechnology.

[75]  B. Tomlinson,et al.  An evaluation of liraglutide including its efficacy and safety for the treatment of obesity , 2019, Expert opinion on pharmacotherapy.

[76]  Naglaa F. Khedr,et al.  New insights into weight management by orlistat in comparison with cinnamon as a natural lipase inhibitor , 2019, Endocrine.

[77]  J. Marier,et al.  A randomized, double‐blind, placebo‐controlled, pharmacokinetic and pharmacodynamic study of a fixed‐dose combination of phentermine/topiramate in adolescents with obesity , 2019, Diabetes, obesity & metabolism.

[78]  K. Saunders,et al.  An up-to-date evaluation of lorcaserin hydrochloride for the treatment of obesity , 2019, Expert opinion on pharmacotherapy.

[79]  J. J. Gorgojo-Martínez,et al.  Effectiveness and tolerability of orlistat and liraglutide in patients with obesity in a real‐world setting: The XENSOR Study , 2019, International journal of clinical practice.

[80]  M. Todtenkopf,et al.  Samidorphan mitigates olanzapine-induced weight gain and metabolic dysfunction in rats and non-human primates , 2019, Journal of psychopharmacology.

[81]  L. Mounien,et al.  Anti-Obesity Effect of Carotenoids: Direct Impact on Adipose Tissue and Adipose Tissue-Driven Indirect Effects , 2019, Nutrients.

[82]  Y. Jia,et al.  Beinaglutide showed significant weight‐loss benefit and effective glycaemic control for the treatment of type 2 diabetes in a real‐world setting: a 3‐month, multicentre, observational, retrospective, open‐label study , 2019, Obesity science & practice.

[83]  D. Fuchs,et al.  Weight Gain During Treatment of Bipolar Disorder (BD)—Facts and Therapeutic Options , 2019, Front. Nutr..

[84]  A. Soukas,et al.  Metformin: Mechanisms in Human Obesity and Weight Loss , 2019, Current Obesity Reports.

[85]  A. Bueno,et al.  Potential Anti-obesogenic Effects of Ginkgo biloba Observed in Epididymal White Adipose Tissue of Obese Rats , 2019, Front. Endocrinol..

[86]  H. Ashrafian,et al.  Current treatments for obesity. , 2019, Clinical medicine.

[87]  D. Majerowicz,et al.  Pharmacotherapy of Obesity: Limits and Perspectives , 2019, American Journal of Cardiovascular Drugs.

[88]  F. Greenway,et al.  Psychiatric adverse events and effects on mood with prolonged-release naltrexone/bupropion combination therapy: a pooled analysis , 2019, International Journal of Obesity.

[89]  Standards of Medical Care in Diabetes—2019 Abridged for Primary Care Providers , 2018, Clinical Diabetes.

[90]  O. Ruban,et al.  Evaluation of anti-obesity and lipid-lowering properties of Vaccinium myrtillus leaves powder extract in a hamster model , 2018, Journal of basic and clinical physiology and pharmacology.

[91]  R. Delorme,et al.  Metformin for Weight Gain Associated with Second-Generation Antipsychotics in Children and Adolescents: A Systematic Review and Meta-Analysis , 2018, CNS Drugs.

[92]  F. Punzo,et al.  Role of Cannabinoids in Obesity , 2018, International journal of molecular sciences.

[93]  Marc P. Bonaca,et al.  Cardiovascular Safety of Lorcaserin in Overweight or Obese Patients , 2018, The New England journal of medicine.

[94]  E. Lara-Padilla,et al.  Anorectic efficacy and safety of the diethylpropion‐topiramate combination in rats , 2018, Drug development research.

[95]  F. Greenway,et al.  Centrally Acting Agents for Obesity: Past, Present, and Future , 2018, Drugs.

[96]  R. Kushner Weight Loss Strategies for Treatment of Obesity: Lifestyle Management and Pharmacotherapy. , 2018, Progress in cardiovascular diseases.

[97]  M. Gulliford,et al.  Antidepressant utilisation and incidence of weight gain during 10 years’ follow-up: population based cohort study , 2018, British Medical Journal.

[98]  M. Alkafafy,et al.  Physiological and molecular study on the anti-obesity effects of pineapple (Ananas comosus) juice in male Wistar rat , 2018, Food Science and Biotechnology.

[99]  S. Cabaro,et al.  Differences in Metabolic Factors Between Antipsychotic-Induced Weight Gain and Non-pharmacological Obesity in Youths , 2018, Clinical Drug Investigation.

[100]  Xiguang Qi Review of the Clinical Effect of Orlistat , 2018 .

[101]  Michelle Pearlman,et al.  The Association Between Artificial Sweeteners and Obesity , 2017, Current Gastroenterology Reports.

[102]  L. Gaal,et al.  Drug-induced obesity and its metabolic consequences: a review with a focus on mechanisms and possible therapeutic options , 2017, Journal of Endocrinological Investigation.

[103]  K. Kim,et al.  Does Weight Gain Associated with Thiazolidinedione Use Negatively Affect Cardiometabolic Health? , 2017, Journal of obesity & metabolic syndrome.

[104]  S. Thomas-Valdés,et al.  Association between vitamin deficiency and metabolic disorders related to obesity , 2017, Critical reviews in food science and nutrition.

[105]  E. Al-Dujaili,et al.  Polyphenols and Their Role in Obesity Management: A Systematic Review of Randomized Clinical Trials , 2017, Phytotherapy research : PTR.

[106]  Xinhua Xiao,et al.  Dietary capsaicin and its anti-obesity potency: from mechanism to clinical implications , 2017, Bioscience reports.

[107]  A. Mehta,et al.  Liraglutide for weight management: a critical review of the evidence , 2016, Obesity science & practice.

[108]  Phang Siew-Moi,et al.  Marine Algae as a Potential Source for Anti-Obesity Agents , 2016, Marine drugs.

[109]  Jeffrey K. Aronson,et al.  Post-marketing withdrawal of anti-obesity medicinal products because of adverse drug reactions: a systematic review , 2016, BMC Medicine.

[110]  F. Araniti,et al.  Effects of Saponins on Lipid Metabolism: A Review of Potential Health Benefits in the Treatment of Obesity , 2016, Molecules.

[111]  M. Pervin,et al.  Beneficial Effects of Tea and the Green Tea Catechin Epigallocatechin-3-gallate on Obesity , 2016, Molecules.

[112]  R. Fain,et al.  Lorcaserin in Obese and Overweight Patients Taking Prohibited Serotonergic Agents: A Retrospective Analysis. , 2016, Clinical therapeutics.

[113]  C. Tek Naltrexone HCI/bupropion HCI for chronic weight management in obese adults: patient selection and perspectives , 2016, Patient preference and adherence.

[114]  S. Simon,et al.  The efficacy of the appetite suppressant, diethylpropion, is dependent on both when it is given (day vs. night) and under conditions of high fat dietary restriction , 2016, Appetite.

[115]  J. Rey,et al.  Naltrexone/Bupropion ER (Contrave): Newly Approved Treatment Option for Chronic Weight Management in Obese Adults. , 2016, P & T : a peer-reviewed journal for formulary management.

[116]  Ralph Mazitschek,et al.  Treatment of Obesity with Celastrol , 2015, Cell.

[117]  N. D’Orazio,et al.  Anti-Obesity Activity of the Marine Carotenoid Fucoxanthin , 2015, Marine drugs.

[118]  Martínez Díaz,et al.  Cost-Effectiveness Analysis of Amfepramone (Diethylpropion) for the Obesity Treatment In Mexico. , 2014, Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research.

[119]  M. Cowley,et al.  Naltrexone/bupropion for obesity: an investigational combination pharmacotherapy for weight loss. , 2014, Pharmacological research.

[120]  D. Segula Complications of obesity in adults: a short review of the literature. , 2014, Malawi medical journal : the journal of Medical Association of Malawi.

[121]  S. Waldman,et al.  Antiobesity Pharmacotherapy: New Drugs and Emerging Targets , 2013, Clinical pharmacology and therapeutics.

[122]  S. Yanovski,et al.  Long-term drug treatment for obesity: a systematic and clinical review. , 2014, JAMA.

[123]  K. Gadde,et al.  Evaluation of phentermine and topiramate versus phentermine/topiramate extended‐release in obese adults , 2013, Obesity.

[124]  Barakatun Nisak Mohd Yusof,et al.  Saffron: A Natural Potent Antioxidant as a Promising Anti-Obesity Drug , 2013, Antioxidants.

[125]  Ariane O Conrad,et al.  Phentermine and topiramate for the management of obesity: a review , 2011, Drug design, development and therapy.

[126]  B. Schehler,et al.  Effectiveness of Metformin on Weight Loss in Non-Diabetic Individuals with Obesity , 2012, Experimental and Clinical Endocrinology & Diabetes (Barth).

[127]  M. Tschöp,et al.  Anti-obesity drugs: past, present and future , 2012, Disease Models & Mechanisms.

[128]  M. Dietrich,et al.  Limitations in anti-obesity drug development: the critical role of hunger-promoting neurons , 2012, Nature Reviews Drug Discovery.

[129]  A. Ismail,et al.  Plants' Metabolites as Potential Antiobesity Agents , 2012, TheScientificWorldJournal.

[130]  J. Kang,et al.  Anti-Obesity Drugs: A Review about Their Effects and Safety , 2012, Diabetes & metabolism journal.

[131]  K. Gadde,et al.  Two-year sustained weight loss and metabolic benefits with controlled-release phentermine/topiramate in obese and overweight adults (SEQUEL): a randomized, placebo-controlled, phase 3 extension study , 2011, The American journal of clinical nutrition.

[132]  J. Ogden,et al.  Taking Orlistat: Predicting Weight Loss over 6 Months , 2010, Journal of obesity.

[133]  J. Crippa,et al.  The psychiatric side-effects of rimonabant. , 2009, Revista brasileira de psiquiatria.

[134]  A. Halpern,et al.  A randomized double-blind placebo-controlled study of the long-term efficacy and safety of diethylpropion in the treatment of obese subjects , 2004, International Journal of Obesity.

[135]  Maurizio Fava,et al.  15 years of clinical experience with bupropion HCl: from bupropion to bupropion SR to bupropion XL. , 2005, Primary care companion to the Journal of clinical psychiatry.

[136]  M. Stock,et al.  Pharmacological characterisation of the thermogenic effect of bupropion. , 2004, European journal of pharmacology.

[137]  S. O’Meara,et al.  A systematic review of the clinical effectiveness of orlistat used for the management of obesity , 2004, Obesity reviews : an official journal of the International Association for the Study of Obesity.

[138]  K. Gadde,et al.  Bupropion for weight loss: an investigation of efficacy and tolerability in overweight and obese women. , 2001, Obesity research.

[139]  R B Haynes,et al.  A randomized trial of improved weight loss with a prepared meal plan in overweight and obese patients: impact on cardiovascular risk reduction. , 2000, Archives of internal medicine.

[140]  M. Korda,et al.  [Status of the free radical oxidation and antioxidant system in rats with toxic liver damage; effect of tocopherol and dimethylsulfoxide]. , 1991, Ukrainskii biokhimicheskii zhurnal.

[141]  J. Vallé-Jones,et al.  A comparative study of phentermine and diethylpropion in the treatment of obese patients in general practice. , 1983, Pharmatherapeutica.